格隆汇2月24日丨正大企业国际(03839.HK)公布截至2025年12月31日止年度之全年业绩。截至2025年12月31日止年度，集团的收入上升74.1%至5亿3,590万美元(2024年：3亿770万美元)。如上所述，集团的收入来自于合并的生物科技业务。收入的大幅增长反映了我们成功地实施及持续执行开发大客户销售的关键策略。收入增长大部分源自动保化药产品的增长。整体毛利率从2024年的15.9%下降至2025年的14.4%。2025年公司股东应占溢利为3,210万美元，而2024年为1,120万美元。溢利上升主要得益于集团生物科技业务的显着增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.